{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-266705","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2026-06-11T11:35:16+00:00","discovered_at":"2026-06-11T11:40:00.268745+00:00","generated_at":"2026-06-11T11:40:11.272532+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Silence Therapeutics reports durable phlebotomy reduction and QoL gains from Phase 1 divesiran study at EHA 2026","bullets":["21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.","Median time to first phlebotomy was 287 days among 14 evaluable patients.","Majority had improved MPN-10 symptom scores through Week 34, indicating better quality of life.","Phase 2 SANRECO (Q6W and Q12W dosing) topline results expected August 2026.","Divesiran well tolerated; mild injection-site reactions, no treatment-related SAEs or discontinuations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-266705","json":"https://secwatch.observer/filing/0001193125-26-266705.json","markdown":"https://secwatch.observer/filing/0001193125-26-266705.md","text":"https://secwatch.observer/filing/0001193125-26-266705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/0001193125-26-266705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/sln-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:40:11.272532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}